Amalgamated Financial’s Day One Biopharmaceuticals DAWN Stock Holding History

Amalgamated Financial’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$30K	Buy	+3,034	New	+$40.1K	﹤0.01%	2621

Other funds holding DAWN

CPX

Canaan Partners XI Menlo Park, California $127M AUM 217.49% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Amalgamated Financial's DAWN Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Day One Biopharmaceuticals (DAWN) in Q1 2022: 3,034 shares worth $30K. The stake represents ﹤0.01% of the portfolio and ranks #2621 among its holdings.

66 funds tracked by Wall St. Rank hold DAWN as of Q1 2022.

Amalgamated Financial held 3,034 shares of Day One Biopharmaceuticals worth $30K as of Q1 2022.
Day One Biopharmaceuticals was a new Amalgamated Financial position in Q1 2022.
Day One Biopharmaceuticals made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2621 holding.
66 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.